Protective effect of silymarin during coronary artery bypass grafting surgery

Experimental and Clinical Cardiology, 04/13/2012

Altaei T – The anti–inflammatory and antioxidant effects of silymarin treatment provided protection against reperfusion injury and inflammation after coronary artery bypass grafting (CABG) surgery.

Methods

  • Of the 102 patients undergoing elective first–time CABG surgery that were recruited, 50 (49.02%) received silymarin treatment and 52 (50.9%) were controls.
  • Plasma cytokine levels (IL–1b, IL–6 and TNF–alpha) were measured preoperatively, 6 h and 24 h after CABG surgery.
  • C–reactive protein (CRP) levels, trolox equivalent antioxidant capacity (TEAC) and glutathione (GSH) and malondialdehyde (MDA) levels were analyzed.

Results

  • Postoperative cytokine levels in the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels.
  • The area under the curve for cytokines and CRP for the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels.
  • Postoperative levels of TEAC and MDA in the silymarin–treated group were significantly lower than in the control group.
  • GSH levels were significantly elevated in the silymarin group compared with control.
  • No side effects or mortality were associated with the use of silymarin.

Go to Abstract Print Article Summary

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List